It seems that it will take time for the ultra-high-priced one-shot treatment Kymriah (Tisagencleucel) to be registered. In particular, it is because the setting of additional financial sharing conditions for pharmaceutical companies, which was not easy in the Cancer Drugs Benefit Appraisal Committee, may pass the Drug Reimbursement Evaluation Committee evaluation.

The HIRA (Director Kim Sun-min) conducted the second Kymriah's standard review at the 7th The Cancer Drugs Benefit Appraisal Committee held on the 13th. Kymriah's standard, which were not set at the 6th Cancer Drugs Benefit Appraisal Committee held on September 1, were set at the 7th Cancer Drugs Benefit Appraisal Committee.

K